The Future of Cancer Therapy: Modular, Safe & Open!

The DeSci Podcast

What if your immune cells came with a smart upgrade?In this episode of the DeSci Podcast, we speak with Dr. Henry Erdlei, medical doctor, cancer researcher, and founder of GoCart, a new cell therapy platform building safer, modular CAR-T therapies through decentralized science.Henry breaks down:* How CAR-T cell therapies work* The real-world risks of immune overactivation* Why cancer is hard to distinguish from healthy tissue* The problem with existing logic gates in cell therapies* His own innovation: an external AND-gate adapter system* Why DeSci and IP-NFTs are the right path for early-stage therapeutics🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at [email protected]:00 – Intro: What is CAR-T therapy?2:00 – Henry’s background & journey into cancer research4:20 – What T-cells do and why they fail in cancer7:30 – CAR-T vs chemotherapy: cost, complexity, and potential11:00 – Which cancers are eligible for CAR-T treatment?13:10 – Risks: cytokine storms, immune cascades, suicide switches17:30 – Emily Whitehead: the first CAR-T success story20:30 – Current limitations of approved CAR-Ts (CD19, BCMA)23:00 – Introducing GoCart and their “AND gate” design26:00 – Why tumor targeting needs precision logic29:00 – Modular CAR-Ts and the future of personalized medicine32:00 – Why GoCart is building in public with Molecule34:30 – Can DeSci unlock truly customizable cell therapies?37:00 – From research to startup: bridging the valley of death40:00 – How to follow GoCart and get involved______Let's connect: Website: https://bit.ly/3d6nh2CTwitter: https://twitter.com/Molecule_daoDiscord: https://discord.gg/ZHGpJQzeTqMolecule - The future of medicine belongs to everyone